Neuroendocrine Tumors Clinical Trial
— EVACELOfficial title:
Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors
NCT number | NCT01678664 |
Other study ID # | FFCD 1104 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | October 2012 |
Est. completion date | April 2019 |
Verified date | March 2020 |
Source | Federation Francophone de Cancerologie Digestive |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Determine wether 24 months treatment with everolimus prolongs progression free survival rate
(based on a central assessment) after embolisation ou chemoembolisation for liver metastases.
- H0 a 24 months progression free survival rate less than 35% is unacceptable
- H1 a 24 months progression free survival rate greater than 35% would show that
everolimus treatment is beneficial, the expected 24 months progression free survival
rate being 50%
Status | Completed |
Enrollment | 74 |
Est. completion date | April 2019 |
Est. primary completion date | September 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Well differentiated (grade 1 and 2 according to WHO classification 2010 appendix 2), histologically-proven endocrine tumor of the gastrointestinal tract (TENpath review mandatory), - Measurable liver metastasis (or metastases) as defined in RECIST v1.1 that are unresectable and inaccessible to radiofrequency ablation-type local treatment - Hepatic arterial embolization or chemoembolization indicated for tumor size reduction, confirmed in an multidisciplinary team (MDT) meeting, due to the progressive nature of the liver metastases (morphological progression during the past 12 months as defined in RECIST v1.1) - Age = 18 years - WHO performance status = 2 - No contraindications to embolization or chemoembolization or everolimus - Satisfactory laboratory assessments:Neutrophil count = 1.5 x 109/L, platelet count = 100 x 109/L, Hb > 10 g/dL, serum bilirubin = 1.5 x the upper limit of normal (ULN), INR < 1.3 (or < 3 for patients on anticoagulant therapy) ALT and AST = 5 x ULN, creatinine = 1.5 x ULN, fasting serum cholesterol = 300 mg/dL or 7.75 mmol/L and triglycerides = 2.5 x ULN (if either or both of these limits are exceeded, the patient may only be included into the study after institution of appropriate lipid-lowering therapy) - Complete resolution of toxic effects of any prior treatments, or persistence at grade 1 at most (CTCAE version 4.0) - Minimum time since previous treatment: 28 days - Patient has been informed and has signed an informed consent form, after verification of the eligibility criteria - Patient covered by a French national health insurance scheme Exclusion Criteria: - Duodenopancreatic neuroendocrine tumor - Poorly differentiated and/or grade 3 endocrine tumor, - Embolization or chemoembolization indicated for symptomatic control only - Prior hepatic TACE or embolization - Prior treatment with an mTOR inhibitor (somatostatin analogs to control secretion are permitted) - Symptomatic bone metastasis (or metastases) - Any uncontrolled progressive disease: hepatic failure, renal failure, respiratory failure, NYHA class III-IV congestive heart failure, unstable angina, myocardial infarction, significant arrhythmia - Interstitial lung disease - Uncontrolled diabetes, defined by HbA1c > 8% - Chronic corticosteroid or immunosuppressant therapy - Hypersensitivity to everolimus, other rapamycin derivatives, or one of the excipients - Major surgery, open biopsy, or significant traumatic lesion during the 28 days prior to starting the investigational treatment Incompletely healed wound or foreseeable need for major surgery during the study - Contraindication to vascular occlusion procedures: Portal thrombosis, biliodigestive anastomosis - Malignancy during the past 5 years, with the exception of curatively treated basal cell skin carcinoma or in situ cervical cancer - Foreseeable non-compliance - Medical, geographic, sociological, psychological, or legal situation that would preclude the patient from completing the study or signing an informed consent form - Pregnant or breast-feeding women - Men or women of child-bearing potential not using effective contraception - Concurrent participation in another investigational study that could affect the primary endpoint of this study |
Country | Name | City | State |
---|---|---|---|
France | CHU - Hôtel Dieu | Angers | |
France | Hôpital Avicenne | Bobigny | |
France | Hôpital Saint André | Bordeaux | |
France | Hôpital Côte de Nacre | Caen | |
France | CHU - Estaing | Clermont Ferrand | |
France | Hôpital Beaujon | Clichy | |
France | Centre GF Leclerc | Dijon | |
France | CHU - Hôpital François Mitterand | Dijon | |
France | Hôpital Edouard Herriot | Lyon | |
France | CHU La Timone | Marseille | |
France | CHR | Orléans | |
France | CHU Cochin | Paris | |
France | Hôpital Européen Georges Pompidou | Paris | |
France | Hôpital Robert Debré | Reims | |
France | CHU | Rouen | |
France | Hôpital Rangueil | Toulouse | |
France | Hôpital Trousseau | Tours | |
France | Institut Gustave Roussy | Villejuif |
Lead Sponsor | Collaborator |
---|---|
Federation Francophone de Cancerologie Digestive |
France,
Walter T, Lepage C, Coriat R, Barbier E, Cadiot G, Caroli-Bosc FX, Aparicio T, Bouhier-Leporrier K, Hentic-Dhome O, Gay F, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C, Di-Fiore F, Ghiringhelli F, Legoux JL, Guimbaud R, Baudin E, Lo — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of hepatic progression free survival at 24 months | Hepatic progression free survival rate as defined in RECIST 1.1 (with death considered as progression) during the 24 months of treatment with everolimus (appendix 3). Progression-free survival rate (PFS) (based on the central assessment) according to RECIST v1.1 according to RECIST v1.1 will be defined as the time from the date of inclusion to the date of hepatic progression or death (due to any cause). For patients who are alive with no hepatic progression, it will be defines as the time from the date of inclusion and the date of the last tumor assessment. |
24 months | |
Secondary | Progression free survival rate (hepatic or not) at 24 months | Progression-free survival rate will be defined as the time from the date of inclusion to the date of disease progression (hepatic or not) evaluated by RECIST V1.1 criteria or death (due to any cause) or the date of the last morphological evaluation for patients who are alive with no disease progression. | 24 months | |
Secondary | Overall survival rate | Overall survival rate shall be defined as the time from the date of inclusion to the date of death, regardless of the cause of death, or the date of last contact for patients who are alive. | 24 months | |
Secondary | Toxicities treatment | the toxicities recorded at each monthly visit, described using -CTCAE version 4.0; grade 3 and 4 toxicities will be reviewed; | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01218555 -
Study of Everolimus (RAD001) in Combination With Lenalidomide
|
Phase 1 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Withdrawn |
NCT04614766 -
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
Recruiting |
NCT05636618 -
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Completed |
NCT02815969 -
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
|
||
Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02174549 -
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02134639 -
PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
|
N/A | |
Completed |
NCT02132468 -
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
|
Phase 2 | |
Recruiting |
NCT01201096 -
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
|
N/A | |
Terminated |
NCT01163526 -
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
|
N/A | |
Completed |
NCT01099228 -
Combination Targeted Radiotherapy in Neuroendocrine Tumors
|
N/A | |
Completed |
NCT00171873 -
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
|
Phase 3 | |
Active, not recruiting |
NCT05077384 -
Open-label Study of Surufatinib in Japanese Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04544098 -
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
|
Early Phase 1 | |
Active, not recruiting |
NCT02736500 -
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 |